BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Arzeda Raises $38M to Meet Strong Market Demand for Better Tasting Stevia

by Roman Kasianov   •   Sept. 17, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Marketing & E-commerce   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Arzeda, a Seattle-based protein design company, has secured $38 million in an oversubscribed funding round to scale up production of its ProSweet Enzymes and ProSweet RebM, which are designed to enhance the taste of stevia.

The funding round attracted new investors, including Sofinnova Partners, Fall Line Capital, Sucden Ventures, Silver Blue, and W.L. Gore & Associates' venture arm, which has partnered with Arzeda since 2022. Existing investors, such as the venture arms of the Continental Grain Company, Bunge Ventures, and Lewis & Clark Agrifood, also participated.

#advertisement
AI in Drug Discovery Report 2025

Michael Krel, Partner at Sofinnova Partners, said:

“Arzeda is at a key inflection point with its products now at commercial scale. This funding will enable Arzeda to accelerate the commercialization of its industrial biotech products, including new designer proteins and enzymes that have the ability to reduce GHG emissions. Arzeda’s Intelligent Protein Design Technology is transformational to many industrial verticals and they are one of the few companies that have been able to translate this promise into commercial products that solve real- world problems and create value for the customer.”

Founded in 2009 by researchers from the University of Washington's Baker Lab, Arzeda applies AI to the field of protein design, aiming to create novel proteins with specific characteristics for a variety of applications beyond traditional biomedical uses. These applications include food, agriculture, home care, and materials, with a focus on replacing conventional chemical-based products with sustainable AI-designed proteins and enzymes.

Image credit: Arzeda

Arzeda also co-founded OpenFold, a non-profit consortium dedicated to developing open-source AI tools for protein structure prediction and design. OpenFold aims to make advanced protein modeling accessible for academic and commercial use, promoting innovation across the biotech and pharmaceutical sectors.

The consortium has developed state-of-the-art AI-based tools such as SoloSeq, a protein Large Language Model integrated with OpenFold’s structure prediction software, and OpenFold-Multimer, which enhances the modeling of protein-protein complexes. OpenFold is also working on an open-source version of AlphaFold3, aiming to create a freely available alternative to proprietary models.

The company’s technology combines AI models guided by biophysics with advanced generative methods, such as LLMs and diffusion models, trained on a proprietary dataset of protein sequences and structures.

Arzeda's current focus is on scaling up its stevia product, a natural sweetener developed using its protein design platform. The company is also working on other products, including laundry detergents for Unilever and biodegradable materials in partnership with W.L. Gore & Associates. By handling both the design and manufacturing processes, Arzeda not only creates proteins and enzymes but also participates in the commercialization of end products in collaboration with its partners.

Topics: Marketing & E-commerce   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.